share_log

Structure Therapeutics | 8-K: Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity

Structure Therapeutics | 8-K: Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity

硕迪生物 | 8-K:Structure Therapeutics 公布 2024 年第三季度财务业绩和近期亮点 ACCESS 20期 GSBR-1290 肥胖症研究首次给药的患者
美股SEC公告 ·  11/14 05:17
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息